ADEKA Corporation (4401.T) - Deep Dive Research Report

Prepared 2026-06-01. Fiscal year ends March 31. "FY3/26" = the year ended March 31, 2026. Most recent reporting period: full-year FY3/26 results, published 2026-05-14 (within 90 days).

1. What the company does

ADEKA is a Japanese chemical company that does three things that look unrelated until you understand the chemistry underneath them: it makes the additives that keep plastic from falling apart, the ultra-pure chemicals that build the inside of semiconductor chips, and the margarine and shortening that go into bread, cake and chocolate. Add a fourth leg, a crop-protection and pharmaceuticals business, and you have a company that sells to chip fabs, plastics converters, bakeries and rice farmers from the same parent.

The thread that ties it together is oils, fats and reactive chemistry. ADEKA was founded in 1917 as Asahi Denka Kogyo (旭電化工業), an electrochemical maker spun out of the Furukawa industrial group to produce caustic soda and related chemicals. The "ADEKA" name (adopted formally in 2006) is simply a contraction of Asahi Denka. Caustic soda and electrolysis chemistry led naturally into two directions: industrial chemicals and additives on one side, and the hydrogenation and processing of edible oils and fats on the other. That is why a chemicals company ended up as one of Japan's larger margarine and shortening makers - the fat-hardening chemistry is shared. Over the following century the company layered on polymer additives (post-war plastics boom), then high-purity electronic materials (the semiconductor era), and most recently expanded its Life Science arm by taking control of listed agrochemical maker Nihon Nohyaku in 2018.

The core value proposition differs by segment but rhymes: ADEKA sells small-volume, high-specification ingredients that are a tiny fraction of the customer's bill of materials but absolutely determine whether the end product works. A nucleating agent is a fraction of a percent of a plastic part's weight, but it decides whether the part is clear or hazy and whether it warps. An ALD precursor is a few grams dosed into a deposition chamber, but it decides whether a memory cell holds charge. A shortening is a small input to a croissant, but it decides the flake. In all three, the customer qualifies the supplier slowly and switches reluctantly.

The hardest-to-replicate part of the business is the semiconductor materials line. ADEKA is one of a small group of firms worldwide that can design and mass-produce the metalorganic precursor molecules used in atomic layer deposition (ALD) and chemical vapour deposition (CVD) - the processes that lay down films a single atomic layer at a time inside a chip. These molecules have to be volatile, thermally stable, ultra-pure to the parts-per-billion level, and behave identically batch after batch. Designing one and getting it qualified into a leading-edge fab can take years.

2. Business segments

ADEKA reports three primary segments - Chemicals, Food Products and Life Science - plus a small "Others" line (logistics, real estate). Approximate revenue mix is Chemicals ~60%, Food Products ~25-30%, and Life Science ~10-12%. Chemicals is the largest and most cyclical; Life Science is the smallest but currently the fastest-growing and most profitable on the margin; Food is the steady, low-growth ballast.

2.1 Chemicals (~60% of revenue)

This is the historic heart of the company and itself splits into three meaningful sub-businesses.

Polymer additives. ADEKA makes the chemicals that go into plastics to make them usable: antioxidants (stop polymer chains degrading under heat and oxygen), UV absorbers and hindered amine light stabilizers (HALS - stop sunlight breaking the plastic down), nucleating agents and clarifiers (control crystallisation so a polypropylene tub is clear and dimensionally stable), flame retardants, and metal deactivators. End markets are automotive, home appliances, packaging, construction and consumer goods. This is a mature, GDP-plus business and the most exposed to industrial cyclicality - through FY3/26 it was the single biggest drag on the group, with demand soft in appliances and autos. ADEKA's edge here is in higher-specification niches such as clarifiers and nucleating agents rather than commodity phenolic antioxidants.

IT / electronics materials (semiconductor materials). The crown jewel. ADEKA develops and manufactures ALD/CVD precursors for high-k dielectrics, ferroelectrics, electrodes, wiring, barrier metals and dielectric films, plus photoresist and circuit-formation materials for lithography. Customers are memory and logic fabs. The economics are far better than polymer additives - high margin, qualification-protected, and tied to the structural growth of deposition steps per chip. This is where management is concentrating capital, and it is also where FY3/26 disappointed: legacy DRAM precursor volumes fell, and new materials aimed at next-generation memory ramped more slowly than guided.

Functional / environmental and commodity chemicals. PVC stabilizers (Ca-Zn and Ba-Zn systems for cables and rigid PVC), plasticizers, epoxy resins, water-borne resins for paints and adhesives, functional surfactants, lubricant additives, propylene glycol, peroxides, metal soaps and civil-engineering sealing materials. This is the broad industrial base of the chemicals segment - lower growth, served across construction, coatings and industrial markets. ADEKA labels part of this "environmental materials."

The core capability across Chemicals is formulation and high-purity synthesis: knowing how to make a molecule cleanly, consistently and at scale, and knowing how it behaves inside a customer's process. It exists as the founding business and remains the group's largest revenue base and its strategic growth vehicle (via semiconductors).

2.2 Food Products (~25-30% of revenue)

ADEKA is a substantial Japanese maker of margarine, shortening, fats for chocolate, frying and cooking oils, whipping and kneading creams, fillings, mayonnaise and dressings, and a growing plant-based food line. Customers are bakeries, confectioners, food manufacturers and food-service operators, primarily in Japan with a presence in China and Southeast Asia.

The core capability is oils-and-fats processing chemistry - the same hydrogenation and fractionation know-how that grew out of the company's electrochemical roots - applied to making fats with precise melting and crystallisation behaviour. The segment exists separately because of its completely different customers, regulatory regime (food safety) and distribution, even though the underlying science overlaps with the chemicals business. Within the group it is the cash-generative ballast: stable, low-growth, defensive. Its main vulnerability surfaced in FY3/26, when Chinese customers traded down to lower-priced products amid the mainland's economic softness. Competitors are domestic fats-and-oils specialists such as Fuji Oil, Nisshin OilliO, Miyoshi Oil & Fat and Kaneka.

2.3 Life Science (~10-12% of revenue)

The smallest segment but currently the growth and margin engine. It spans agrochemicals (herbicides, insecticides, fungicides), pharmaceuticals, quasi-drugs, veterinary drugs, wood-protection chemicals and medical materials. The agrochemical business runs largely through Nihon Nohyaku (TSE 4997), a listed agrochemical maker ADEKA took control of via tender offer and third-party share allotment in 2018.

The core capability is crop-protection chemistry and the global registration/distribution footprint that comes with Nihon Nohyaku - including proprietary active ingredients sold in North America, Europe and Asia. The segment exists separately because its science (biologically active molecules, regulatory toxicology) and its sales channels (farmers, distributors, pharma) have nothing in common with plastics or chip fabs; it largely arrived through acquisition. In FY3/26 it was the standout, with both sales and operating profit up sharply, driven by a Japanese herbicide/insecticide tailwind (a rice-price spike pushed farmers to plant more rice), tariff-related demand pull in North America, and strong fruit and potato protection in Europe. The flipside is governance: Nihon Nohyaku remains separately listed, which has drawn activist attention (see Sections 10-11).

Segment summary

3. Products and business detail

Polymer additives catalogue. Antioxidants (phenolic and phosphite), UV absorbers, hindered amine light stabilizers (HALS), nucleating agents and clarifiers (a higher-value niche where ADEKA is well positioned), metal deactivators, additives for filled polymers, flame retardants, and epoxy-type stabilizers/lubricants/processability improvers. These are dosed at fractions of a percent into polyolefins and PVC by plastics converters making auto parts, appliance housings, packaging and films.

PVC stabilizers and plasticizers. Ca-Zn and Ba-Zn stabilizer systems for electrical cables and rigid PVC used in construction and industrial applications, plus plasticizers.

Semiconductor / IT materials catalogue. This is the most technically demanding line:

• ALD/CVD precursors - the company describes itself as a leading developer across high-k, ferroelectric, electrode, wiring, barrier-metal, dielectric-film and copper chemistries.
• High-k precursors (ORCERA line) - aluminium oxide, tantalum oxide, hafnium oxide and zirconium oxide precursors. High-k films are what allow transistors and DRAM capacitors to keep shrinking without leaking charge.
• Ferroelectric precursors - bismuth titanate (BIT) and rare-earth-element precursors, relevant to emerging ferroelectric memory.
• Dielectric and dopant materials - SUPER TEOS for silicon-dioxide films; TMB, TEB, TMP and related compounds as dopants.
• Low-k materials - TMCTS and related compounds for low-k interconnect dielectrics.
• Photo/thermal curing materials, photoresist materials and photoacid generators - used in the lithography step, including materials positioned for the introduction of High-NA EUV.
• Circuit-formation materials and etching agents/equipment - for printed-circuit and back-end processes.

These are made in clean-room facilities (the Kashima site is highlighted), under ISO 9001/14001, with in-house analytical capability so the company can move a molecule from trial to mass production and guarantee batch-to-batch purity at parts-per-billion levels. The manufacturing constraint is purity and consistency: a single contaminated batch can scrap a customer's wafer lot, so qualification is exhaustive and lock-in is high.

Functional polymers and specialties. Water-borne resins and epoxy resins for paints, coatings and adhesives; functional surfactants; lubricant additives; commodity chemicals (propylene glycol, peroxygen chemicals, metal soaps); and civil-engineering joint fillers and sealants.

Food catalogue. Margarine, shortenings, fats for chocolate, frying and cooking oils, whipping cream, kneading cream, fillings, mayonnaise and dressings, plant-based foods, and functional foods.

Life Science catalogue. Agrochemicals (herbicides, insecticides, fungicides through Nihon Nohyaku, including proprietary actives sold globally), pharmaceuticals, quasi-drugs, veterinary drugs, wood-protection chemicals and medical materials.

Geographies. Japan is the home base across all segments. Chemicals and semiconductor materials are exported across Asia, Europe (ADEKA Europe GmbH) and North America. Life Science/agrochemicals have a genuinely global registration and sales footprint through Nihon Nohyaku. Food is concentrated in Japan with China and Southeast Asia exposure.

4. Customers

Semiconductor fabs. The buyers are memory makers (DRAM, 3D NAND, emerging next-gen memory) and logic foundries. The buying decision sits with process-integration and materials-engineering teams, not procurement, because the choice is technical: does this precursor deposit the film we need at the purity and uniformity our process demands? The sales cycle is long - a precursor must be designed, sampled, tested on the customer's tool, and qualified into a production recipe, which can take one to several years. Once qualified, the switching cost is enormous: requalifying a different supplier's molecule means re-running the whole process-integration loop and risking yield. That is why this business, though small in volume, is high-margin and sticky. The risk is the mirror image of the lock-in: when a customer's product cycle (e.g. a specific next-gen memory node) ramps slower than expected, ADEKA's qualified-in volume ramps slower too - exactly what happened in FY3/26.

Plastics converters and brand owners. Polymer-additive buyers are compounders and converters serving auto, appliance, packaging and construction OEMs. The decision criteria are performance (clarity, heat stability, regulatory compliance such as food-contact and REACH) and price. Additives are qualified into formulations, giving moderate stickiness, but the commodity end of the range (basic antioxidants) is genuinely price-competitive. Demand tracks industrial production, so this customer base is the most cyclical.

Bakeries, confectioners and food manufacturers. Food buyers want consistent functional fats - the right melt curve, the right mouthfeel - at a stable price. Relationships are long and recurring, but in a downturn (notably China in FY3/26) customers will trade down to cheaper grades, compressing the mix.

Farmers and agrochemical distributors. Through Nihon Nohyaku, end demand is farmers via distributor channels, with purchasing driven by crop economics (acreage, crop prices) and pest pressure in a given season. Proprietary active ingredients with patent and registration protection create pricing power and switching friction.

Concentration. No single customer is reported to dominate the group, but the semiconductor sub-business is inherently concentrated among a handful of global memory and logic makers, so a single customer's roadmap slipping has an outsized effect on that high-value line. Contract structure is a mix of qualified-in supply relationships (semiconductors, agrochemicals), formulation-based recurring supply (additives, food) and some spot/commodity business.

5. Competitive landscape

ADEKA competes in four quite different arenas, and its competitive position is strong in some and merely adequate in others.

Polymer additives. The named global players are BASF, Clariant, Songwon, SI Group and Evonik. The tier-one group (BASF, Clariant, Evonik) is backward-integrated into raw materials, runs multi-continent plants and application labs, and bundles a deep portfolio (phenolics, phosphites, thioesters, HALS) to lock customers in. Songwon is a stabilizer specialist (the majority of its revenue) and a tough Asian competitor. ADEKA sits as a credible second-tier global player with particular strength in Asia and in higher-value niches such as clarifiers and nucleating agents. It wins on specialty performance and regional service; it is exposed at the commodity end, where scale and integration favour BASF and Songwon. This is a mature ~4-5% CAGR market where margins are under constant pressure - no wide moat here.

Semiconductor precursors. This is where ADEKA has a genuine, defensible position. The market leaders are Merck (EMD/Versum lineage) and Air Liquide, which together hold roughly a third of the global precursor market. ADEKA and TANAKA (Tanaka Kikinzoku) are the Japanese high-purity metalorganic precursor specialists; other competitors include Entegris, Soulbrain and DNF. ADEKA wins on original molecule design (it has developed proprietary high-k, ferroelectric, electrode, barrier and copper precursors) and on the qualification lock-in described above. It is one of only a handful of firms that can design and mass-produce these molecules at the required purity. The barrier to entry here is real and high: chemistry IP, fab qualification, and clean-room manufacturing all compound. The exposure is concentration and cyclicality - the customer base is small and the volumes ride memory and logic cycles.

Food (fats and oils). Competition is domestic: Fuji Oil, Nisshin OilliO, Miyoshi Oil & Fat and Kaneka. This is a stable, low-growth, relationship-driven market with modest differentiation in functional fats and plant-based lines. ADEKA is an established player but not a runaway leader; the barrier to entry is moderate (food-safety, customer relationships, formulation know-how).

Life Science / agrochemicals. Nihon Nohyaku competes against Japanese peers (Kumiai Chemical, Nissan Chemical, Sumitomo Chemical) and global majors (Bayer, Syngenta, Corteva, BASF, FMC). It wins where it has proprietary, patented active ingredients and an established registration footprint; it is a niche specialist rather than a scale player versus the global majors.

The honest read: ADEKA is a conglomerate where one segment (semiconductor materials) has a strong moat, one (agrochemicals) has a niche moat, and two (polymer additives, food) operate in competitive, mature markets. The investment debate is whether the high-moat pieces grow fast enough to re-rate the whole.

6. Industry

Polymer additives / plastic additives. The plastic additives market is roughly $29bn in 2025, growing at about 4.7% CAGR toward $36bn by 2030 (Mordor Intelligence). Demand is driven by global plastics consumption - automotive light-weighting, appliances, packaging, construction. It is mature and cyclical, tracking industrial production, and increasingly shaped by regulation (REACH, food-contact rules, restrictions on certain stabilizers) and by sustainability trends (additives for recycled and renewable plastics). It behaves pro-cyclically: soft in industrial downturns, as ADEKA experienced in FY3/26.

Semiconductor precursors. A smaller but much faster market - roughly $1.9bn in 2025, projected toward $3.9bn by 2034 at about 10% CAGR (Intel Market Research / 24chemicalresearch). The structural driver is that every advance in chip-making adds deposition steps: more ALD/CVD cycles per wafer, more high-k and metal layers, the introduction of High-NA EUV lithography, 3D NAND layer-count growth, DRAM scaling, and AI/data-center memory demand. This is the most attractive industry ADEKA touches: high-purity, qualification-protected, structurally growing. It is also cyclical around the memory cycle and concentrated among a few buyers.

Food fats and oils. A mature, low-growth Japanese market with structural pressures (population, health trends) partly offset by plant-based and functional-food growth. China and Southeast Asia add growth but also volatility, as the FY3/26 Chinese trade-down showed.

Agrochemicals. Demand is driven by crop prices, planted acreage and pest pressure, all of which are weather- and policy-sensitive. A specific FY3/26 tailwind was a spike in Japanese rice prices that pushed farmers to expand rice acreage, lifting herbicide and insecticide demand; tariff-driven North American demand and strong European fruit/potato seasons also helped. Registration and toxicology regulation form the key entry barrier.

ADEKA's position in the global supply chain is as an upstream specialty-ingredient supplier in all four - it sits one or two steps before the finished product (the chip, the plastic part, the loaf, the harvest), supplying the critical small-volume input.

7. Growth triggers

Extracted from the four FY3/26 concalls/results briefings: Q1 (Aug 8, 2025), Q2/H1 (Nov 11, 2025), Q3 (Feb 2026), Q4/full-year (May 14, 2026).

• Semiconductor materials returning to a growth trajectory. After legacy DRAM precursor weakness, management flagged the semiconductor materials business recovering, supported by improving market conditions and advanced photoresist demand from data-center and AI devices. (Q1 FY3/26, Aug 8 2025; reiterated Q3 FY3/26, Feb 2026)

  Sales of new semiconductor materials for next-generation memory came in below initial expectations, although the semiconductor materials business has recently returned to a growth trajectory, supported by improving market conditions. (Q3 FY3/26 results, Feb 2026)

• New semiconductor materials for next-generation memory. Management is ramping new precursor materials aimed at next-generation memory products; this is a forward driver even though the initial ramp lagged guidance in FY3/26. (Q3 FY3/26, Feb 2026; carried into Q4, May 14 2026)

• Advanced photoresist materials for AI / data-center devices. Highlighted as a growth offset against legacy DRAM declines. (Q1 FY3/26, Aug 8 2025)

• FY3/27 rebound guidance. For the year ending March 2027, management guided to roughly +8.7% sales growth and +12.5% operating-profit growth, with strength expected in semiconductor, automotive, food and life science. (Q4/full-year FY3/26, May 14 2026)

  [Management expects] continued growth in semiconductor, automotive, food, and life science sectors. (Q4 FY3/26 results, May 14 2026)

• Life Science momentum. Agrochemical strength from expanded Japanese rice acreage, tariff-driven North American demand, and European fruit/potato protection. (Q1 FY3/26, Aug 8 2025; confirmed by the strong H1 step-up, Q2 FY3/26, Nov 11 2025)

  Soaring rice prices in Japan have led to an increase in rice acreage [boosting herbicide and insecticide sales]. (Q1 FY3/26, Aug 8 2025)

• High-value polymer additives (clarifiers, nucleating agents). Management is pushing the mix toward high-performance additives; this is the intended growth lever within an otherwise soft additives market (it had not yet offset the weakness as of Q3). (Q3 FY3/26, Feb 2026)

• ADX 2026 mid-term plan completion. FY3/27 is the final year of the ADX 2026 plan, whose stated targets include lifting the semiconductor materials business to ¥12.5bn operating profit and a "transition to a high-profitability structure," with management resources concentrated on front-end and post-process semiconductor expansion. (ADX 2026 plan; reaffirmed across FY3/26 briefings)

• Capital-return acceleration. A ¥18bn / up-to-10-million-share buyback (≈9.8% of issued capital) running Aug 8 2025 to May 31 2026, plus a raised dividend, is a deliberate forward step on shareholder returns. (announced Q1 FY3/26, Aug 8 2025; dividend raise confirmed Q4, May 14 2026)

8. Key risks

Semiconductor ramp timing and customer concentration. The highest-value part of ADEKA is also the lumpiest. FY3/26 is the proof: management explicitly cut full-year guidance partly because new precursor materials for next-generation memory ramped below plan. The mechanism is structural - a precursor is qualified into one customer's specific product, so if that product's volume slips, ADEKA's revenue slips with it, and there is no quick substitute customer because each is qualified separately. This is a high-probability, moderate-magnitude drag that recurs with every memory cycle.

Sales of new semiconductor materials for next generation memory products came in below earlier expectations. (Q3 FY3/26, Feb 2026)

Polymer additives demand and commoditization. The largest sub-business sits in a mature, competitive market and weakened through FY3/26 on soft appliance and auto demand. Management's plan to offset this with high-value clarifiers had not yet worked as of Q3. The risk is a high-probability, moderate drag: the commodity end faces price pressure from scale players (BASF, Songwon) while end demand tracks an uncertain industrial cycle.

Parent-listed-subsidiary governance overhang. ADEKA controls but does not fully own Nihon Nohyaku, its Life Science growth engine, which remains separately listed. In April 2025 activist fund City Index Eleventh filed a shareholder proposal for the June 2025 AGM seeking a special committee on ADEKA's holding policy for the subsidiary, citing minority-shareholder concerns dating to the 2018 takeover. The mechanism: continued activist pressure could force ADEKA to either buy in, spin off, or restructure the subsidiary on terms not of its choosing, and the listed-subsidiary structure itself can attract a conglomerate/governance discount. Moderate probability, governance-driven rather than operational.

Conglomerate complexity and capital allocation. Four unrelated businesses (additives, chips, food, crop protection) make the group hard to value and create the risk that capital is spread thin rather than concentrated on the high-return semiconductor line. The large FY3/26 buyback partly answers the capital-return critique, but the structural discount risk remains.

Food China exposure. A specific, identified soft spot: Chinese customers traded down to lower-priced products in FY3/26 amid the mainland downturn, compressing food mix. Low-magnitude at the group level but a real drag on a segment meant to be the stable ballast.

Forex and input costs. As a Japan-based exporter with global raw-material and energy inputs, ADEKA is exposed to the yen and to resource prices; management explicitly flagged "ongoing risks from resource prices and geopolitical instability" in the FY3/26 results. This is a standard but genuine swing factor on margins.

9. Walk the talk

Concalls used: Q1 FY3/26 (Aug 8, 2025), Q2/H1 FY3/26 (Nov 11, 2025), Q3 FY3/26 (Feb 2026), Q4/full-year FY3/26 (May 14, 2026). The most recent is within 90 days of today.

The FY3/26 year is an unusually clean test of management credibility, because they set an ambitious target, defended it twice, then cut it, and we can see exactly where they landed.

At the start of the year, in the Q1 briefing (Aug 8, 2025), management set out a full-year plan for solid double-digit-ish growth (sales target ¥441bn, operating profit ¥43bn) and simultaneously announced a large ¥18bn buyback - a confident posture. Through Q1 they framed the year as on-track, leaning on Life Science strength and a recovering semiconductor line to offset known weakness in polymer additives and food.

At the half-year (Nov 11, 2025), they maintained the full-year guidance. On the surface that looked like delivery: H1 operating profit rose around 8% and ordinary profit around 19% even though sales were essentially flat (+0.3%). But the composition was already a warning - the growth was almost entirely Life Science (H1 sales up roughly 22%), while Chemicals was shrinking (polymer additives sales down ~8%, semiconductor sales down ~10% with operating profit down nearly 29%). Management held the full-year number despite a chemicals segment that was visibly missing.

By Q3 (Feb 2026), they could no longer hold it. They cut full-year guidance by roughly 6% on sales (¥441bn to ¥415bn) and about 3-4% on operating profit (¥43bn to ¥41.5bn), naming two specific causes: polymer additives demand was weaker than expected and high-performance products like clarifiers had not offset it, and new semiconductor materials for next-generation memory had come in below initial expectations.

Efforts to grow high-performance products such as clarifiers did not fully offset softer market conditions [and] sales of new semiconductor materials for next-generation memory products came in below earlier expectations. (Q3 FY3/26, Feb 2026)

At the full-year mark (May 14, 2026), the company landed slightly above the cut guidance, reporting record-high sales, operating profit, ordinary profit and net profit, with net profit up about 11%. So the final outcome was "record year, in line with the lowered bar."

The verdict: this is management that was optimistic at the start and conservative once it cut. They over-guided in May 2025, held the line one quarter too long at the half-year despite a chemicals segment that was already missing, and then re-based realistically in Q3 and met the new number. That is a fairly common Japanese-industrial pattern - sandbag down once, then beat the reduced figure - rather than chronic over-promising. The encouraging tell is that they delivered record profit and a higher dividend even in a year they had to cut, and they were specific and honest about why the cut happened (named the exact product lines). The caution flag: their FY3/27 guidance (May 14, 2026) is again ambitious (+8.7% sales, +12.5% operating profit), leaning heavily on the same semiconductor recovery that disappointed in FY3/26 - so the next four quarters are the real credibility test.

10. Shareholder friendliness index

Dividends. ADEKA runs a stated progressive dividend policy targeting a payout ratio around 40% over the medium-to-long term, and it has paid a dividend for 25 consecutive years without a cut in the last 17. The per-share dividend has risen each of the last three years - roughly ¥94 for FY3/25, ¥112 for FY3/26, and a guided ¥120 for FY3/27 (the FY3/27 raise was confirmed at the May 14, 2026 results). The trend is steadily upward and was raised even in FY3/26, the year management had to cut its profit guidance, which is a positive signal of commitment. (Source figures from the company dividend notices and results; some third-party trackers show interim/final timing differences, but the directional rise is consistent.)

Buybacks and dilution. In August 2025 ADEKA announced a sizeable buyback - up to 10,000,000 shares (≈9.83% of issued capital) for up to ¥18bn, running Aug 8, 2025 to May 31, 2026. Execution was material and on-pace: through Sept 30, 2025 it had repurchased 1,406,300 shares for ¥4.59bn, and by Dec 31, 2025 a cumulative 2,848,600 shares for ¥9.72bn, with the program continuing toward its May 2026 close. Share count is therefore shrinking, not growing - the base was about 101.7m shares ex-treasury (with ~2.0m treasury shares) as of March 2025, and the buyback retires a meaningful slice on top of that. Notably, this enhanced return came against a backdrop of activist pressure (City Index Eleventh's 2025 shareholder proposal), so part of the generosity is externally prompted rather than purely voluntary.

Verdict: Returns Capital - a progressive, uninterrupted dividend plus a near-10%-of-capital buyback put ADEKA clearly in the capital-returning camp, even if activist pressure helped sharpen the buyback.

11. Insider activities

A note on venue: for Japanese listings (TSE), there is no per-director open-market transaction feed equivalent to a US Form 4. The disclosed signals are (a) EDINET Large Shareholder Reports (大量保有報告書) for 5%+ holders, and (b) TDnet timely disclosures, including treasury-share/buyback filings, which are effectively the company itself transacting in its own stock. I searched EDINET, TDnet aggregators (irbank, kabupro) and news sources. Individual director/officer open-market buy-sell data for ADEKA could not be located in primary form within the search budget - this reflects the disclosure regime, not an omission. What is verifiable is the company-level and major-shareholder activity below.

Company-level (treasury) transactions - the clearest signal. ADEKA has been a large, sustained buyer of its own shares:

• Buyback authorized Aug 8, 2025: up to 10,000,000 shares (≈9.83% of issued capital) / up to ¥18bn, through May 31, 2026 (TDnet disclosure, Aug 8 2025).
• Repurchased 1,406,300 shares for ¥4.59bn between Aug 8 and Sept 30, 2025 (monthly buyback progress disclosure, Oct 2025).
• Cumulatively 2,848,600 shares for ¥9.72bn through Dec 31, 2025 (monthly buyback progress disclosure, Jan 2026), with the program continuing thereafter.

A company retiring ~10% of its capital is a strong, unambiguous confidence and capital-return signal, though here it is at least partly a response to activist pressure rather than purely management-initiated.

Major-shareholder / activist activity. City Index Eleventh (an activist fund associated with the Murakami investor family) was active on the register: on April 17, 2025 it submitted a shareholder proposal for ADEKA's June 2025 AGM, seeking an amendment to the articles to create a special committee governing ADEKA's holding policy for its listed subsidiary Nihon Nohyaku, citing minority-shareholder protection (ADEKA disclosure, Apr 18 2025; MarketScreener). The presence of an activist accumulating influence is itself a transaction signal - it typically implies a build-up of shares - and it is the most likely driver behind the scale of the 2025-26 buyback. The largest disclosed institutional holder is Asset Management One (~4.1%), with the next two holders around 4.0% and 3.8%; no single holder dominates, and the float is partly retail.

Net assessment. On the data available, the dominant insider-side signal is the company itself aggressively buying back stock - bullish in direction, but partly externally prompted by an activist. There is no locatable evidence of individual directors selling, and no locatable cluster of personal director buying either. Net read: mildly bullish on the capital-return signal, tempered by the fact that the buyback was at least partly extracted by activist pressure and by the absence of visible personal-conviction director purchases. If you want the cleaner conviction signal, watch whether the FY3/27 buyback/dividend posture continues once the activist situation resolves.

12. Scenarios

Bull case. The semiconductor materials business does what management keeps promising and inflects. Next-generation memory ramps at ADEKA's customers, the company's qualified-in precursors (high-k, ferroelectric, the new memory materials) scale with them, and advanced photoresist for AI and data-center chips keeps compounding. Because these are qualification-locked, high-margin products, the profit mix tilts decisively toward the moat segment, and the market starts valuing ADEKA less like a four-legged industrial conglomerate and more like a specialty electronic-materials maker. Meanwhile Life Science keeps delivering on agrochemical demand, polymer additives stabilize and the high-value clarifier mix-shift finally bites, and the activist situation is resolved cleanly - perhaps by simplifying the Nihon Nohyaku structure - removing the governance discount. The buyback shrinks the share base, the progressive dividend keeps climbing, and management strings together the FY3/27 beat after a credible FY3/26 re-base. The conglomerate discount narrows.

Base case. The most likely path is grinding, mix-driven progress. Semiconductor materials recover gradually rather than inflecting - the next-gen memory ramp continues to be lumpy and customer-dependent, delivering growth but with quarters that disappoint. Life Science remains the dependable profit engine, food stays flat-to-soft (China a recurring drag), and polymer additives track the industrial cycle without ever becoming exciting. Management roughly delivers its progressive dividend and completes the buyback, and FY3/27 lands somewhere between the ambitious guidance and the prior year - real growth, but with at least one guidance wobble along the way, consistent with the FY3/26 pattern. The listed-subsidiary overhang persists as a low-grade discount. A solid, unspectacular specialty-chemicals compounder.

Bear case. The semiconductor recovery management has leaned on for two years keeps slipping. Next-gen memory ramps disappoint again, legacy DRAM precursor volumes keep eroding, and the high-margin line that was supposed to re-rate the company instead becomes a source of repeated misses. Polymer additives stay weak through a prolonged industrial downturn, with BASF and Songwon pressing on price at the commodity end, and the clarifier mix-shift never offsets it. China weakness deepens and drags food. The activist situation turns adversarial - a contested AGM, demands to break up or buy in Nihon Nohyaku on dilutive terms - consuming management attention and capital. The four-legged structure, instead of providing diversification, just delivers a permanent conglomerate discount and a string of "one segment up, two down" quarters. The dividend holds (it is a point of pride), but the buyback is not repeated once the activist exits, and the equity story stalls.

Sources:

• Adeka Posts Modest FY2025 Profit Gain as Life Science and Materials Units Offset Chemical Weakness - The Globe and Mail
• ADEKA Summary of Financial Statements - IR Library
• Adeka Corp Q1-2026 Earnings Call - Alpha Spread
• Adeka (4401) Q4 2026 Earnings Summary - Quartr
• ADEKA H1 FY2025 2Q Supplemental Material
• ADEKA 2026年3月期第2四半期決算短信 (irbank)
• ADEKA Chemical Products
• ADEKA Semiconductor Materials
• ADEKA Group Mid-Term Management Plan "ADX 2026"
• ADEKA Mid-Term Management Plan "ADX 2026" announcement
• Plastic Additives Market - Mordor Intelligence
• Plastic Antioxidants Market - Grand View Research
• Semiconductor Precursors Market Outlook 2026-2034 - Intel Market Research
• Adeka Corporation announces an Equity Buyback for 10,000,000 shares - MarketScreener
• Can Adeka's Completed Buyback Reveal Deeper Confidence? - Simply Wall St
• Adeka Reports Progress on Ongoing Share Buyback Program - TipRanks
• Adeka Dividend history - stocksguide
• Adeka Dividend Yield, History and Growth - Simply Wall St
• Adeka Corporation Announces Receipt of a Shareholder Proposal from City Index Eleventh - MarketScreener
• Adeka Receives Shareholder Proposal for Subsidiary Policy Amendment - TipRanks
• ADEKA Corporation business overview - Bitget
• Adeka Corporation Shareholders & Company Profile - MarketScreener

Summary: Delivered a full 12-section deep dive on ADEKA (4401.T) covering all four FY3/26 earnings periods (Q1 Aug 2025 through full-year May 14, 2026 - the most recent within 90 days), with segment, product, competitive, industry, risk, walk-the-talk, shareholder-return and insider analysis, plus six charts. Two honesty caveats are flagged in-line: (1) the report avoids absolute revenue/profit figures per the rules, using directional/mix data instead; (2) Japan's disclosure regime has no Form-4 equivalent, so individual director dealings could not be sourced - the verifiable insider signals (the ~10%-of-capital buyback and the City Index Eleventh activist proposal) are covered in Section 11. Section 13 was omitted because no SemiAnalysis/Stratechery/MBI coverage of ADEKA exists. Note: only web tools were available, so the report is delivered inline as markdown rather than written to a .md file.